Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Geospatial correlation of industrial plastics emissions with bladder and kidney cancer burden in Ohio.

Urologic oncology·2026
Same author

Simultaneous Presentation of Hemophagocytic Lymphohistiocytosis and Classical Hodgkin's Lymphoma in a Patient with Underlying Germline Homozygous STXBP2 Mutation.

Mediterranean journal of hematology and infectious diseases·2026
Same author

NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Breaking the bonds: targeting protein dimerization for prostate cancer therapy.

Endocrinology·2026
Same author

Novel single stage multipath 8 × 8 interconnection network/switching element (SSMIN/E) architecture.

Scientific reports·2026
Same author

Re: Bertolo R, Pastore AL, Verze P, et al. Real-world Burden and Management of Late Genitourinary Toxicity after Prostate Radiotherapy: Insights from IRRADIaTE, the Italian Registry of Radiotherapy-associated Disorders and Urological Treatment & Evaluation. Eur Urol Oncol. 2026;9:408-416. http://dx.doi.org/10.1016/j.euo.2026.01.005.

European urology oncology·2026

Related Experiment Video

Updated: Aug 30, 2025

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

11.9K

PAM50 and Beyond: When Will Tissue Transcriptomics Guide Clinical Decision-making?

Samuel C Haywood1, Shilpa Gupta2, Hannelore V Heemers3

  • 1Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.

European Urology Focus
|August 28, 2022
PubMed
Summary
This summary is machine-generated.

Emerging transcriptomics classifiers show promise for guiding prostate cancer clinical decisions. Further research, optimization, and validation are needed for these novel biomarkers.

More Related Videos

Working with Human Tissues for Translational Cancer Research
07:48

Working with Human Tissues for Translational Cancer Research

Published on: November 26, 2015

10.0K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.0K

Related Experiment Videos

Last Updated: Aug 30, 2025

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

11.9K
Working with Human Tissues for Translational Cancer Research
07:48

Working with Human Tissues for Translational Cancer Research

Published on: November 26, 2015

10.0K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.0K

Area of Science:

  • Oncology
  • Genomics
  • Biomarker Discovery

Background:

  • Prostate cancer diagnosis and treatment decisions rely on accurate prognostic and predictive information.
  • Current methods for prostate cancer prognostication have limitations.
  • Transcriptomics-based approaches offer a novel avenue for improving clinical decision-making.

Purpose of the Study:

  • To evaluate the potential of emerging transcriptomics-based classifiers as biomarkers in prostate cancer.
  • To assess the utility of these classifiers in guiding clinical decision-making for prostate cancer patients.

Main Methods:

  • Analysis of gene expression profiles in prostate cancer samples.
  • Development and application of novel transcriptomics-based classifiers.
  • Assessment of classifier performance for predicting clinical outcomes.

Main Results:

  • Emerging transcriptomics-based classifiers demonstrate promising potential as biomarkers.
  • These classifiers show promise in aiding clinical decision-making processes for prostate cancer.

Conclusions:

  • Transcriptomics-based classifiers represent a promising area for prostate cancer biomarker development.
  • Further research, optimization, and validation are essential before widespread clinical implementation.